CD8-positive T-cell
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer.
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer. CD8 strengthens interactions between the T-cell receptor and peptide–major histocompatibility complex class I (MHC I) molecules displayed by nucleated cells. Following antigen recognition and appropriate co-stimulation, CD8⁺ T cells can differentiate into cytotoxic effector cells, memory T cells, or dysfunctional/exhausted states. Effector CD8⁺ T cells eliminate infected or transformed cells through cytotoxic granules and death-receptor pathways and can produce cytokines such as interferon gamma and Tumor necrosis factor-α (TNF-α).
CD8⁺ T cells are central components of antiviral and antitumor immunity. Their activity is shaped by antigen-presenting cells, particularly dendritic cells capable of cross-priming, as well as by the tumor microenvironment, regulatory T cells, macrophages, transforming growth factor, metabolic conditions, and immune-checkpoint pathways. In cancer, CD8⁺ T cells may recognize tumor-associated or tumor-specific antigens, but their function can be limited by inhibitory receptors such as LAG3 and TIGIT, suppressive signaling involving CD274 molecule, nutrient competition, and lactate accumulation. These properties make CD8⁺ T cells important targets and effectors of immunotherapy, including adoptive tumor-infiltrating lymphocyte (TIL) therapy, checkpoint inhibitor treatment, cytokine-based agents, and approaches designed to improve dendritic-cell priming.
Where the papers sit
11 papers from the last 6 months study CD8-positive T-cell directly · updated from PubMed 16 Oct 2026
Study type 1 clinical trial · 1 human data · 8 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Tumor Immunotherapy Resistance
Checkpoint response is being reframed around the tumor matrix, cytoskeleton and metabolism rather than PD-1 status alone. LOXL4-driven stiffening can suppress CD8 function, while acetyldigoxin is reported to restore it in lung cancer. Cofilin1 remodeling and cuproptosis are proposed determinants of immunotherapy response or resistance. LAG-3/PD-1-positive CD8 cells nevertheless associate with better gastric-cancer prognosis, leaving biomarker direction context-dependent.
4 papers · 36.4%
-
Localized AAV Immune Activation
Local AAV delivery is being explored to alter antigen presentation or trigger CD8 activation in specific tissues. In medulloblastoma, interferon restores MHC class I and sensitizes tumors to T-cell killing. In muscle, activation appears within 24 hours and depends on promoter specificity. The shared focus is tissue-localized immune engagement, while durability and safety remain open.
2 papers · 18.2%
-
Others — T-Cell States and Therapy
Tumor-reactive CD8 T cells are being separated into terminal exhaustion and durable memory, with phenotype and function used to predict TIL-therapy benefit. Therapeutic activation is pursued through TGR5-dependent dendritic-cell cross-priming and a TIGIT-targeted IL-12 fusion protein that engages NK and CD8 cells. Clonal CX3CR1-positive expansion also appears in anti-NMDA receptor encephalitis, extending the focus beyond cancer. The group shares T-cell state and activation biology but not a single clinical setting.
5 papers · 45.5%
CD8-positive T cells can create, rather than merely exploit, tumor-cell susceptibility to therapy
The medulloblastoma model studied by the local-interferon delivery paper and the cuproptosis-immunity systems studied by the cuproptosis paper both replace the usual one-way picture in which CD8-positive T cells act only as downstream killers of tumor cells. In medulloblastoma, CD8-derived IFN-γ restores tumor-cell MHC class I and thereby enables T-cell killing; in cuproptosis models, the same cytokine induces tumor-cell FDX1 and increases sensitivity to cuproptosis, while cuproptotic death further stimulates antitumor immunity 42735303Sep 42330950Jun. The resulting change is conceptual as well as therapeutic: CD8-positive T-cell activity is itself a mechanism for remodeling tumor vulnerability and can determine whether otherwise ineffective tumor-directed treatments work.
CD8-positive T cells are identified as clonally expanded pathogenic effectors in anti-NMDA receptor encephalitis
The anti-NMDA receptor encephalitis study uses single-cell transcriptomic, T-cell-receptor and epitope profiling to assign CD8-positive T cells a disease-driving role outside the set's dominant tumor-immunity and therapeutic-response frameworks. It identifies clonally expanded CX3CR1-expressing CD8-positive T cells in cerebrospinal fluid as disease-associated effectors with predicted GluN1-epitope reactivity, cytotoxic and proinflammatory programs, and interaction with activated B cells, rather than treating them as incidental immune participants 42711907Sep. This redirects attention toward CD8-positive T cells as potential mediators of autoimmune neuroinflammation and therapeutic resistance in anti-NMDA receptor encephalitis.
Papers
The 11 papers from the last 6 months that study CD8-positive T-cell directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Tumor Immunotherapy Resistance (4)
- Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
- Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
Localized AAV Immune Activation (2)
- Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Others — T-Cell States and Therapy (5)
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907
- Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
- TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
- Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 May 2026 PMID 42149143
By study type
Clinical trials (1)
- Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 May 2026 PMID 42149143
Human data, design not indexed (1)
- Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
Preclinical: animal, cell and lab studies (8)
- Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
- Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
- Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Unclassified: not yet indexed with MeSH (1)
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.